This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In the 1860s, Trousseau first described the association between cancer and a hypercoagulable state.1 Ironically, he later diagnosed himself with phlebitis and predicted his own death from pancreatic cancer. Secretion of procoagulants by tumor cells, vascular damage secondary to immune response, and iatrogenic injury from chemotherapeutic agents, radiotherapy, and in-dwelling catheters, among other mechanisms, may contribute to hypercoagulability in the setting of cancer.2 This places oncology patients at high risk of cerebrovascular phenomena, which frequently leads to patients' initial diagnosis.3 Despite this well-defined risk in patients with cancer, the incidence of recurrent thromboembolism and its effect on overall survival have received little attention.4
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the editorial.
See page 26
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Recurrent thromboembolic events after ischemic stroke in patients with cancer
Recurrent cerebral ischemia in medically treated patent foramen ovale
Recurrent stroke in symptomatic carotid stenosis awaiting revascularization
Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke